Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
Text
Humira® (adalimumab) – Expanded orphan indication
September 28, 2018 - The FDA approved AbbVie’s Humira (adalimumab) for the treatment of non-infectious intermediate, posterior, and panuveitis in adults and pediatric patients 2 years of age and older.
